Journal article 171 views 22 downloads
Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
,
Sagen Zac‐Varghese,
Khuram Chaudhry,
Kieran McCafferty,
Peter Winocour ,
Tahseen A. Chowdhury ,
Srikanth Bellary,
Gabrielle Goldet,
Mona Wahba,
Parijat De,
Andrew H. Frankel,
Rosa M. Montero,
Eirini Lioudaki,
Debasish Banerjee ,
Ritwika Mallik,
Adnan Sharif,
Naresh Kanumilli,
Nicola Milne,
Dipesh C. Patel,
Ketan Dhatariya ,
Steve Bain ,
Janaka Karalliedde
Diabetic Medicine, Volume: 42, Issue: 2, Start page: e15450
Swansea University Author:
Steve Bain
-
PDF | Version of Record
© 2024 The Author(s). This is an open access article under the terms of the Creative Commons Attribution License (CC BY 4.0).
Download (616.61KB)
DOI (Published version): 10.1111/dme.15450
Abstract
A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes‐related CKD is a leading cause of end‐stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Despite...
| Published in: | Diabetic Medicine |
|---|---|
| ISSN: | 0742-3071 1464-5491 |
| Published: |
Wiley
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa68024 |
| Abstract: |
A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes‐related CKD is a leading cause of end‐stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Despite advances in care over the recent decades, most people with CKD and type 2 diabetes are likely to die of CVD before developing ESKD. Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. People with type 2 diabetes often have dyslipidaemia and CKD per se is an independent risk factor for CVD, therefore people with CKD and type 2 diabetes require intensive lipid lowering to reduce burden of CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated a reduction in composite kidney end point events (significant decline in kidney function, need for kidney replacement therapy and kidney death) with sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors, non‐steroidal mineralocorticoid receptor antagonist finerenone and glucagon‐like peptide 1 receptor agonists. The Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the management of hyperglycaemia, hyperlipidaemia and hypertension in adults with type 2 diabetes and CKD. This 2024 abbreviated updated guidance summarises the recommendations and the implications for clinical practice for healthcare professionals who treat people with diabetes and CKD in primary, community and secondary care settings. |
|---|---|
| Item Description: |
Invited Review |
| Keywords: |
ACE inhibitor, hypertension, kidney disease, lifestyle, type 2 diabetes |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
2 |
| Start Page: |
e15450 |